Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Complement System

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Steroid hormones in Alzheimer's disease: a molecular analysis of blood and cerebrospinal fluid.

Alzheimer's research & therapy·2026

Same author

Retraction notice to "Fate, bioaccumulation and toxicity of engineered nanomaterials in plants: Current challenges and future prospects" [Sci. Total Environ. 811 (2022) 152249].

The Science of the total environment·2026

Same author

Unravelling sex differences in the genetic architecture of anxiety.

Psychological medicine·2026

Same author

Genome-wide meta-analysis of quantitatively measured generalized anxiety symptoms in individuals of European ancestry.

Nature human behaviour·2026

Same author

The contribution of apolipoprotein E genetic variation to dementia risk in British South Asians.

Brain communications·2026

Same author

Polyol pathway dysregulation in CSF links glucose metabolism to tau pathology independently of amyloid and genetic predisposition.

medRxiv : the preprint server for health sciences·2026

Search research articles

Related Experiment Video

Updated: May 30, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Complement activation as a biomarker for Alzheimer's disease.

Mohammed Aiyaz¹, Michelle K Lupton, Petroula Proitsi

¹Kings College London Institute of Psychiatry, De Crespigny Park, London, UK.

|August 23, 2011

Summary

Complement activation plays a key role in Alzheimer's disease (AD) pathogenesis. Its potential as a biomarker for early detection and therapeutic development in AD is discussed.

More Related Videos

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Related Experiment Videos

Last Updated: May 30, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Area of Science:

Neuroscience
Immunology
Biochemistry

Background:

Alzheimer's disease (AD) pathogenesis involves complex biological processes.
The complement cascade, a part of the innate immune system, is increasingly implicated in AD.
Complement proteins are found in brain amyloid plaques, indicating early involvement.

Purpose of the Study:

To review the role of complement activation in Alzheimer's disease.
To explore the potential of complement activation as a biomarker for AD.
To discuss the implications for novel therapeutic strategies.

Main Methods:

Review of genetic, immunohistochemical, proteomic, and epidemiological studies.
Analysis of findings from model systems.
Examination of the dual role of complement in amyloid clearance and inflammation.

Main Results:

Evidence suggests complement activation is integral to AD pathogenesis.
Complement cascade may act protectively in amyloid clearance or causally via inflammation.
Complement activation is present at the earliest stages of AD.

Conclusions:

Complement activation holds potential as a biomarker for AD across disease stages.
Accurate biomarkers are crucial for developing and testing effective AD therapies.
Targeting complement pathways could offer novel therapeutic avenues for AD.